Front Row Advisors LLC Vericel Corp Transaction History

Front Row Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$41.71 - $52.9 $750 - $952	-18 Reduced 14.75%	104 $4,000
Q1 2024 May 14, 2024	BUY	$32.52 - $52.33 $3,967 - $6,384	122 New	122 $6,000
Q2 2023 Aug 14, 2023	BUY	$29.0 - $38.37 $58 - $76	2 Added 2.0%	102 $4,000
Q1 2023 May 22, 2023	BUY	$23.85 - $31.34 $2,313 - $3,039	97 Added 3233.33%	100 $3,000
Q1 2023 May 15, 2023	SELL	$23.85 - $31.34 $2,385 - $3,134	-100 Reduced 97.09%	3 $10,000
Q3 2022 Nov 15, 2022	BUY	$22.62 - $32.54 $588 - $846	26 Added 33.77%	103 $2,000
Q2 2022 Aug 15, 2022	BUY	$22.88 - $39.45 $137 - $236	6 Added 8.45%	77 $2,000
Q1 2022 May 11, 2022	BUY	$31.69 - $43.29 $2,249 - $3,073	71 New	71 $2,000

277

48.4M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.6B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Front Row Advisors LLC with notifications on news.